Board of Directors

Michael Wolff Jensen (born 1971) has 20 years of experience from strategic leadership from Pharma/Biotech – as CFO, Chairman of the Board, responsible partner and as Chief Legal Officer. Michael has been main responsible for four IPOs; Genmab (Nasdaq Copenhagen and Neuer Markt Frankfurt 2000), LifeCycle Pharma (Nasdaq Copenhagen 2006), Ascendis Pharma (Nasdaq US 2015) and Xspray Pharma (Nasdaq First North Stockholm 2017 and Nasdaq Main Market Stockholm 2020). He has also been responsible for several funding rounds and in total raised more than 20 billion SEK. Furthermore, Michael has more than 15 years of experience as board member and as chairman, both in private and publicly traded companies.

Holdings in Vicore: None

Share awards: 350.000

Education: Law degree, University of Copenhagen

Other assignments: SVP / Chief Legal Officer of Ascendis Pharma AB (publ). Chairman of VISEN Pharmaceuticals and MIWO Invest.

Independent in relation to both the Company and its management as well as to major shareholders.

Heidi Hunter (born 1958) has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution.  Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability. Heidi has a unique, multicultural and global experience of engaging people from different cultures to work towards the same vision and goals.

Holdings in Vicore: None

Share awards: 175.000

Education: M.B.A., Marketing and International Business, The University of Chicago. ?B.A., Economics and German, Magna cum laude, The University of Michigan

Other assignments: SVP, Global Immunology Business Unit at UCB, Belgium.

Independent of the company and its senior management and independent of major shareholders of the company.

Maarten Kraan has extensive experience in biomedicine and has, among others, held a senior position at AstraZeneca AB where he was responsible for the research and development of medicines for respiratory, inflammatory and autoimmune symptoms. Maarten is currently CMO at AM-Pharma a clinical stage Biotech.

Shareholdings: –

Share awards: 125,000

Education: Doctor’s degree in rheumatology at the University of Leiden.

Other assignments: Maarten Kraan is a board member of Toleranzia AB and CDS Gmbh.

Independent of the company and its senior management and independent of major shareholders of the company.

Jacob Gunterberg is a partner at HealthCap since 2007 and has extensive experience in venture capital investment operations and corporate finance in life science. Jacob Gunterberg is, among others, a board member of HealthCap Orx Holdings GP AB, Carisma Therapeutics Inc., Sgnox Therapeutics Ltd., Tribune Therapeutics AB and former chairman of INIM Pharma AB.

Shareholdings: –

Share awards: –

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments: Partner at HealthCap. Board member inEllAug AB, Tova Skrenen Stockholm AB, Ancilla AB and Skipjack AB.

Independent of the company and its senior management but dependent of major shareholders of the company.

Mr. Schikan is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He previously served on the boards of Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion), Swedish Orphan Biovitrum, Sweden and Therachon (acquired by Pfizer).

Shareholdings: –

Share awards: 125,000

Education: Pharmacist degree (PharmD) from the University of Utrecht.

Other assignments:Chairman of InteRNA Technologies BV, Microbiotica Ltd and Complix NV. Board member of VectivBio AG, Pharvaris NV and the Dutch Top Sector Life Sciences & Health. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.